

See discussions, stats, and author profiles for this publication at: <https://www.researchgate.net/publication/259351340>

# Expression of glutathione S –transferase variants in human airway wall after long-term response to sulfur mustard

Article in *Journal of Receptor and Signal Transduction Research* · December 2013

DOI: 10.3109/10799893.2013.864677 · Source: PubMed

CITATIONS

8

READS

97

4 authors:



**Mohammad Reza Nourani**

Baqiyatallah University of Medical Sciences

136 PUBLICATIONS 1,250 CITATIONS

[SEE PROFILE](#)



**Sadegh Jamalkandi Azimzadeh**

Baqiyatallah University of Medical Sciences

60 PUBLICATIONS 261 CITATIONS

[SEE PROFILE](#)



**Mostafa Ghanei**

Baqiyatallah University of Medical Sciences

391 PUBLICATIONS 5,607 CITATIONS

[SEE PROFILE](#)



**Abbas Ali Imani Fooladi**

Baqiyatallah University of Medical Sciences

256 PUBLICATIONS 2,147 CITATIONS

[SEE PROFILE](#)

Some of the authors of this publication are also working on these related projects:



Effect of Antioxidants on COPD treatment success [View project](#)



Biomimetic modification of polyurethane-based nanofibrous vascular grafts: A promising approach towards stable endothelial lining [View project](#)

# PROOF COVER SHEET

---

Author(s): Mohammad Reza Nourani, Sadegh Azimzadeh, Mostafa Ghanei, and Abbas Ali Imani Fooladi

Article title: Expression of glutathione S-transferase variants in human airway wall after long-term response to sulfur mustard

Article no: LRST\_A\_864677

Enclosures: 1) Query sheet  
2) Article proofs

---

Dear Author,

**Please check these proofs carefully.** It is the responsibility of the corresponding author to check against the original manuscript and approve or amend these proofs. A second proof is not normally provided. Informa Healthcare cannot be held responsible for uncorrected errors, even if introduced during the composition process. The journal reserves the right to charge for excessive author alterations, or for changes requested after the proofing stage has concluded.

The following queries have arisen during the editing of your manuscript and are marked in the margins of the proofs. Unless advised otherwise, submit all corrections using the CATS online correction form. Once you have added all your corrections, please ensure you press the “Submit All Corrections” button.

---

Please review the table of contributors below and confirm that the first and last names are structured correctly and that the authors are listed in the correct order of contribution.

Contrib. No.	Prefix	Given name(s)	Surname	Suffix
1		Mohammad Reza	Nourani	
2		Sadegh	Azimzadeh	
3		Mostafa	Ghanei	
4		Abbas Ali	Imani Fooladi	

## AUTHOR QUERIES

- Q1: Please check whether the suggested running head is ok.
- Q2: As per style a maximum of 4 authors name should be listed in reference list; if more than four authors then list first three authors followed by et al. Please provide the authors name accordingly in all the references.
- Q3: Please provide volume number and page range for Ref. 2.
- Q4: Please provide journal title for Ref. 46.
- Q5: Please check whether the citation suggested for figure 2 is correct.
- Q6: Please provide last page number for reference 34.
- Q7: Please provide better quality artwork of figure 2.

8 RESEARCH ARTICLE

10 **Expression of glutathione S-transferase variants in human airway wall**  
11 **after long-term response to sulfur mustard**

14 Mohammad Reza Nourani<sup>1</sup>, Sadegh Azimzadeh<sup>1</sup>, Mostafa Ghanei<sup>1</sup>, and Abbas Ali Imani Fooladi<sup>2</sup>

16 <sup>1</sup>Chemical Injuries Research Center and <sup>2</sup>Applied Microbiology Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran

18 **Abstract**

19 *Context:* Sulfur mustard (SM) is an alkylating agent identified as a potent chemical warfare  
20 agent. More recently, SM was used in the Iraq conflict against Iranian troops and civilians.  
21 At present, there are many people suffering from chronic obstructive pulmonary disease  
22 (COPD) due to mustard gas in Iran. SM increases the endogenous production of reactive  
23 oxygen species (ROS). The oxidant/antioxidant imbalance present in the lungs of these patients  
24 also results from the impaired capacity of the antioxidant/detoxification enzymes to detoxify  
25 the harmful reactive oxygen metabolites. *Objective:* One of the major antioxidants in  
26 human airways is glutathione S-transferase. They facilitate the detoxification of various  
27 environmental of oxidative stress. In this study, we attempted to understand the significance  
28 different in expression of GSTs in airway wall of chemical patients and control.  
29 *Materials and methods:* Seven normal and 20 SM induced COPD individuals were studied.  
30 Bronchoscopy was performed in all subjects and two specimens were taken from the  
31 main bronchus for mRNA extraction, PCR analysis and immunohistochemistry. *Results:*  
32 SM-induced COPD individuals showed expression of GSTA1  $2.51 \pm 0.83$ -, GSTM1  $2.84 \pm 1.71$ -  
33 and GSTP1  $5.61 \pm 2.59$ -folds higher than those of controls that revealed. GSTP1-immunore-  
34 activity was strongly expressed in luminal border of normal samples. SM patient samples  
35 immunoreactivity for GSTP1 in the same area were negative. *Discussion and conclusion:*  
36 According to these findings, we speculated that overexpression of GSTs mRNA in patients  
37 revealed that GSTs plays an important role in cellular protection against oxidative stress of MS  
38 in airway wall of patients.

38 **Introduction**

39 Sulfur mustard (SM) is a strong alkylating and vesicant agent  
40 which has been used in several military conflicts. It was first  
41 synthesized in 1822 by Despretz and modified in 1860 by  
42 Niemann and Guthrie. More recently, mustard was used in the  
43 Iraq–Iran conflict against Iranian troops and civilians.  
44 Nowadays, over 100 000 Iranians are suffering from SM late  
45 signs. This agent causes acute and chronic complications with  
46 special characteristics including inflammation, fibrosis and  
47 airway remodeling most similar to chronic obstructive  
48 pulmonary disease (COPD) (1–3). COPD is a progressive  
49 and irreversible airflow limitation which is usually associated  
50 with dysregulated inflammatory response of lungs to noxious  
51 particles or gases (4–6). Although COPD affects the lungs, it  
52 induces significant systemic consequences such as chronic  
53 inflammation and oxidative stress, inextricably linked  
54 together (7,8).

18 **Keywords**

Airway, glutathione S-transferase, sulfur  
mustard

18 **History**

Received 27 August 2013  
Revised 6 November 2013  
Accepted 7 November 2013  
Published online ■■■

Reports indicate that SM increases the endogenous  
production of reaction oxygen species (ROS) (9), which  
derives oxidative stress and inflammation (10). Accordingly,  
oxidative stress depletes cellular detoxifying thiol levels  
including glutathione. Provision and availability of scavengers  
of ROS and electrophilic compounds such as glutathione,  
sulfhydryl compounds, antioxidants and substances that  
increase the production of endogenous scavengers may be  
considered as appropriate protective strategy (11). Studies  
imply oxidant–antioxidant imbalance as an important argue in  
the pathogenesis of COPD (12). This event results from the  
impaired capacity of the antioxidant/ detoxification enzymes  
to detoxify the harmful reactive oxygen metabolites (13,14).  
Very little is known about specific changes in the major  
antioxidant defense mechanisms in mild or severe COPD.  
One of the major antioxidants in human airways is glutathione  
S-transferase. This large family of phase II enzymes facilitates  
the detoxification of various environmental toxins and  
oxidative stress products. However, the regulatory mechan-  
isms controlling the intra- and extra-cellular concentrations of  
GST are not completely understood (15,16). But in mammals,  
there are currently five known families of soluble GSTs,  
Alpha, Mu, Pi, Sigma and Theta, each with distinct catalytic

Address for correspondence: Abbas Ali Imani Fooladi, Applied  
Microbiology Research Center, Baqiyatallah University of Medical  
Sciences, Tehran, Iran. E-mail: imanifooladi.a@gmail.com

121 and structural properties. The most abundant mammalian  
122 GSTs are the class alpha, mu and pi enzymes and their  
123 regulation has been studied in more details (17).

124 GSTA1 provide protection against oxidative stress by  
125 attenuating lipid peroxidation and modulating apoptosis  
126 signaling in small cell lung cancer (18). Moreover, the  
127 polymorphisms of GSTM1, and P1 have been associated with  
128 lung, bladder, breast and colon cancers (19). The GSTM1 null  
129 genotype was reported to be associated with emphysema (20).  
130 The GSTP1 105Ile allele has been associated with COPD in  
131 Japanese population (21). However, Yim and colleagues  
132 reported that none of the GSTM1 and GSTP1 polymorphisms  
133 were associated with COPD in a Korean population (22–24).  
134 Furthermore, glutathione *S*-transferase P1 (GSTP1), the  
135 abundant isoform of glutathione *S*-transferases (GSTs) in  
136 lung epithelium, plays important role in the cellular protection  
137 against oxidative stress and toxic foreign chemicals.  
138 Seemingly, GSTP1 roles in allergic asthma as well as non-  
139 allergic subtypes by modulation of ROS production (25).

140 To the best of our knowledge, there is no report of *GST*  
141 gene polymorphism and its interaction with SM gas on lung  
142 function in adults. In this study, we tried to find out the  
143 significant difference among GSTA1, M1 and P1 expression  
144 in COPD complications induced by SM gas.

## 146 Materials and methods

### 147 Subjects and selection

148 This study comprised 20 SM-exposed patients and 7 healthy  
149 participants. The exposed patients were injured by single dose  
150 of mustard gas individuals who had a documented encounter  
151 with SM within the Iran–Iraq war. The mean age of normal  
152 subjects was  $41.3 \pm 2.5$  years, and SM-induced patients were  
153 male with a mean age of  $43.2 \pm 6.4$  years summarized in  
154 Table 1.

155 Patients with other chronic pulmonary diseases (such as  
156 asthma), lung cancer, autoimmune diseases (such as rheuma-  
157 toid arthritis), diabetes mellitus, pneumonia or acute infective  
158 bronchitis were excluded. In addition smokers, addicts, elders,  
159 organ transplant recipients or patients with occupational  
160 history of toxic fume exposure also were excluded. Finally,  
161 7 normal and 20 SM-induced COPD individuals were  
162 selected in a protocol approved by ethics committee of  
163 Baghiyatallah University of Medical Sciences.

### 166 Bronchoscopy biopsy sampling and handling

167 Bronchoscopy was performed in all subjects using flexible  
168 fiber-optic bronchoscope 5 (Olympus Biopsy forceps  
169 FB-15 C-1, Tokyo, Japan), according to our previous study  
170 (26). Briefly, the upper respiratory tract was anesthetized with  
171 2% lidocaine. Then, atropine (0.75 mg intramuscularly) was  
172 administered before the procedure. Also, supplemental  
173 oxygen was given throughout the procedure, and the oxygen

174 Table 1. Characteristics of SM-injured patients and control group.

177 Groups	178 N	178 Sex (M/F)	178 Age range	178 Age mean $\pm$ SD	178 p
179 Control group	7	6/1	39.0–44.0	41.3 $\pm$ 2.5	0.64
180 SM-injured group	20	20/0	36.0–58.0	43.2 $\pm$ 6.4	

181 saturation was monitored by continuous pulse oxymeter. Two  
182 specimens were taken from the sub-segmental carinae of  
183 lower lobe. One of them was immediately immersed into the  
184 Tripure isolation reagent (Roche Diagnostics GmbH, Foster  
185 City, CA) and stored at  $-80^{\circ}\text{C}$  until RNA extraction and  
186 another one was immersed into the 4% buffered paraformal-  
187 dehyde for immunohistochemical analysis.

### 188 RNA extraction

189 Total RNA of biopsy was extracted by Tripure isolation  
190 reagent (Roche Diagnostics GmbH), according to the manu-  
191 facturer. Sample concentration and purity were determined by  
192 optical density (OD) measurement at 260 nm by NanoDrop  
193 spectroscopy (ND-1000, Wilmington, DE). Then, total RNA  
194 quality was checked on 1% agarose gel stained with ethidium  
195 bromide.

### 198 cDNA synthesis

199 Reverse transcription was performed by SuperScript III  
200 reverse transcription (Invitrogen, Carlsbad, CA) with 1  $\mu\text{g}$  of  
201 total RNA followed by DNaseI (Invitrogen) treatment and  
202 heat inactivation in order to eliminate any chromosomal DNA  
203 contamination.

### 206 Assessment of GSTs expression

207 Semiquantitative PCR was performed using Taq DNA  
208 polymerase (Takara, Japan) in a PCR system (mastercycler  
209 ep, Ependorf, Germany), by initial denaturation (30 s at  
210  $95^{\circ}\text{C}$ ), annealing (30 s at  $55^{\circ}\text{C}$  for human GSTs and  $59^{\circ}\text{C}$  for  
211  $\beta$ -actin), extension (1 min at  $72^{\circ}\text{C}$ ) and terminal extension  
212 (5 min at  $72^{\circ}\text{C}$ ) in 30 cycles. Primer set for the human GSTs  
213 were: GSTA1, 5'-GTGCAGACCAGAGCCATTCTC-3' (for-  
214 ward), 5'-GCAAGCTTGGCATCTTTTTCC-3' (reverse);  
215 GSTM1, 5'-ATGCCCATGATACTGGGGTAC-3'(forward),  
216 5'-GTGAGCCCCATCAATCAAGTAG-3' (reverse); GSTP1,  
217 5'-ACCTCCGCTGCAAATACATCTC-3' (forward), 5'-GGC  
218 TAGGACCTCATGGATCAG-3' (reverse). For the normal-  
219 ization, expression of  $\beta$ -actin was examined and the primer  
220 set as forward 5'-TTCTACAATGAGCTGCGTGTGG-3' and  
221 reverse 5'-GTGTTGAAGGTCTCAAACATGAT-3'. PCR  
222 products were separated in 2% agarose gel and dyed with  
223 ethidium bromide and then detected under UV light. All  
224 results were normalized with  $\beta$ -actin expression to compen-  
225 sate for differences in the amount of cDNA. For quantitative  
226 measures and evaluation, PCR results on gel were

227 Table 2. Results of pulmonary function test in SM-injured patient and  
228 control group.

232	232 Control group subjects, n = 15	232 SM-injured patients, n = 24	232 p Value
233 FVC (mean $\pm$ SD)	3.34 $\pm$ 0.79	2.87 $\pm$ 0.89	0.11
234 FEV1 (mean $\pm$ SD)	2.71 $\pm$ 0.81	1.92 $\pm$ 0.87	0.007*
235 FEV1/FVC (mean $\pm$ SD)	79.85 $\pm$ 6.15	67.88 $\pm$ 15.81	0.001*
236 RV (mean $\pm$ SD)	2.38 $\pm$ 0.97	3.75 $\pm$ 1.75	0.04*

237 FVC, forced vital capacity; FEV1, forced expiratory volume in 1 s; RV,  
238 residual volume; SD, standard deviation.

239 \* $p < 0.05$ .



241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300




Figure 1. Expression levels of GSTA1, GSTM1 and GSTP1 in patients with long-term exposure to sulfur mustard. Total RNAs were purified and then were analyzed by semiquantitative RT-PCR. This panel shows gel bands in order to PCR amplification products of GSTA1 (170 bp), GSTM1 (204 bp), GSTP1 (206 bp) and  $\beta$ -actin (115 bp) transcripts. (A) Marked increase in GSTA1 expression levels of SM-exposed patients (lanes 3–13) was recognized in comparison to expression level of unexposed cases (lanes 1 and 2). (B) The density band of GSTM1 in SM-exposed patients also shows highlighted deference with mRNA of unexposed group. GSTP1 also shows the deference in mRNA expression level. (E) B-actin was used as internal control. Lane M shows DNA ladder (100 bp).

densitometered by using special Image Analysis software (Scion Corporation, Frederick, MD).

**Immunohistochemistry analysis**

For immunohistochemistry, details were already described elsewhere by us (43,44), briefly individual airway wall biopsies were fixed with 4% buffered paraformaldehyde for fixation for one day. The biopsies were cryoprotected by immersed overnight in a phosphate buffer containing 30% sucrose to prevent the formation of ice crystal artifact in frozen tissue section. Sections of 20  $\mu$ m thickness were cut on a cryostat microtome (Histo line, Milano, Italy) and incubated with monoclonal anti mouse GSTP1-antibody (Santa Cruz Biotechnology Inc., Santa Cruz, CA) at a dilution 1:200, for 12 h at 4  $^{\circ}$ C. After incubation with the primary antibody, the sections were incubated with biotinylated anti-mouse secondary antibody IgG (Santa Cruz Biotechnology Inc). The sections were subsequently visualized using ABC complex (avidinbiotinylated peroxidase complex) system (Vector Laboratory, Burlingame, CA) with DAB as a substrate.

**Statistical analysis**

Results are revealed as mean  $\pm$  SD of fold changes of each gene were analyzed using the SPSS statistical package (version 13.0; SPSS Inc., Chicago, IL) and Mann-Whitney *U* test was used to compare the differences between groups ( $p < 0.05$ ).

COLOR  
Online  
B&W in  
Print




Figure 2. SM-induced COPD individuals showed expression of GSTA1 2.51  $\pm$  0.83, GSTM1 2.84  $\pm$  1.71 and GSTP1 5.61  $\pm$  2.59 folds higher than those of controls.

301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357  
358  
359  
360

## Results

### Subject clinical characteristics

Totally, 27 cases were participated in this study. There were 20 SM exposed patients and 7 normal controls. There was no statistically difference between the average ages of two groups (Table 1). Pulmonary function testing showed no difference in airflow limitation between groups, although SMs had positive methacholine challenge and/or evidence of spontaneous airway reactivity. Bronchoscopy was performed in all individuals without complications. However, the results of pulmonary function testing are shown in Table 2. Although forced vital capacity in the control group was higher than in SM-injured cases, but the difference was not statistically significant ( $p=0.11$ ). On the other hand, forced expiratory volume in 1 second (FEV1) in the SM group was significantly lower than in the controls ( $p=0.007$ ). Moreover, FEV1/forced vital capacity also differed between the two groups, being significantly higher in the controls ( $p=0.001$ ). Residual volume was significantly elevated in SM-injured patients in comparison with controls ( $p=0.04$ ).

### Overexpression of GSTs mRNA

The expressions of GSTs were assessed by semi-quantitative RT-PCR on total RNA extracted from fresh airway biopsy of healthy controls and SM-induced COPD individuals. GSTA1, GSTM1 and GSTP1 mRNAs were present at expected sizes of 170, 204 and 206 bp, respectively. Specific primers were used to achieve full length human GSTs (Figure 1). SM-induced COPD individuals showed expression of GSTA1  $2.51 \pm 0.83$ , GSTM1  $2.84 \pm 1.71$  and GSTP1  $5.61 \pm 2.59$ -folds higher than those of controls that reveal (Figure 2). According to these findings, we speculated that GSTs mRNA overexpression in airway wall biopsy was due to oxidative stress induction.

### Immunohistochemistry analysis

To examine whether SM induces GSTP1 expression in protein level immunohistochemistry analysis was performed. GSTP1-immunoreactivity was strongly localized in luminal border of epithelial cells and numerous cells vicinity to basement membrane was also immunopositive to GSTP1 of normal samples. SM patient samples immunoreactivity for GSTP1 in




Figure 3. Light micrograph of GSTP1-immunopositive cells in the bronchial epithelium. (A) GSTP1-immunoreactivity in bronchial epithelial cell of control group. GSTP1-immunopositivity strongly demonstrated in luminal border of epithelium and substantial number of cells vicinity to basement membrane (BM). In epithelial cells of chemical injured patients no immunoreactions are seen throughout the section. Note that the thickness of epithelial cell layer in experimental group is higher than control group due to chemical injury. BM, basement membrane.



the same area and cells were negative, so in particular the epithelial cells reveal immunonegative reactivity for GSTP1 (Figure 3).

## Discussion

An emerging body of evidence indicates that COPD, asthma and respiratory infections increase pulmonary and systemic levels of oxidative stress (27–31). The recent finding that SM increases the endogenous production of ROSs (9,45) has suggested that ROSs are likely involved in this toxicity (10,11). The imbalance between oxidant and antioxidant systems is suggested to be involved in the pathophysiology of SM-induced pulmonary lesions. Thus, several studies have shown the importance of oxidative stress in the pathogenesis of COPD whose signs and symptoms are similar to delayed pulmonary sequels observed in SM-injured patients (32–34,46).

This study provides an outstanding opportunity to investigate the effect of gene–gene interactions and interaction of genotype with SM exposure on severity of lung function impairment in patient with airflow obstruction. Almost, most of SM-induced COPD patients reveal a significant difference pulmonary function tests such as FEV<sub>1</sub>, FVC and FEV<sub>1</sub>/FVC with control group and this clinical finding confirmed that COPD is presented on SM exposed patients. Moreover, we found that the variants of GSTs were associated with low pulmonary function. There have been a variety of proposals that genetic variations are responsible for detoxifying harmful inhaled agents and there are important factors that affect this genetic predisposition of COPD. The most important of these enzymes are glutathione S-transferase family. GSTs have been associated with COPD and asthma as an important enzymatic antioxidant in the airflow limitation pathogenesis at older ages (20,21,35,36) which functions as an antioxidant in xenobiotic, peroxide and hydroperoxides metabolism pathways to reduce oxidative stress (29,30).

Our finding reveals that, GSTA1 genotype is expressed 2.51 ± 0.83, GSTM1 2.84 ± 1.71 and GSTP1 5.61 ± 2.59-fold higher than those of controls group. GSTA1 provide protection against oxidative stress by attenuating lipid peroxidation (18). In a cytotoxicity study (37), GSTA1 up-regulated against administration of environmental contaminants and in an immunohistochemistry study on smokers. The distribution of the class A enzymes was widest of all the GSTs studied, extending from the epithelium of the central bronchi to the type 1 and type 2 alveolar epithelium. GSTA1/A2 was also seen in bronchial and vascular smooth muscle and in alveolar macrophages (38). This could suggest that GSTA1 isoform has detoxification role against environmental contaminants.

Based on prior studies, we identified three candidate GSTs based on a hypothesis about pathways involved in lung function (17,35,39–42). The results of the present investigation extends our previous knowledge about GSTs role in protecting human pulmonary system against toxic metabolites (17).

## Conclusion

We hypothesized that excess oxidative stress provides a mechanistic framework that unifies interrelationships between asthma and respiratory infections, and environmental exposures such as air pollution, tobacco smoke and SM inhalation,

and factors such as diet and genetics (39). Our findings support the proposed mechanistic framework and the usefulness of studies focusing on genes involved in oxidative stress pathways.

## Declaration of interest

None of the authors has a financial relationship with a commercial entity that has an interest in the subject of this manuscript.

## References

- Zhang J, et al. Pro-inflammatory phenotype of COPD fibroblasts not compatible with repair in COPD lung. *J Cell Mol Med* 2012;16:1522–32.
- van den Berge M, et al. Clinical and inflammatory determinants of bronchial hyperresponsiveness in COPD. *Eur Respir J* 2012.
- Valvi D, et al. Fibrinogen, chronic obstructive pulmonary disease (COPD) and outcomes in two United States cohorts. *Int J Chron Obstruct Pulmon Dis* 2012;7:173–82.
- Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. *Eur Respir J* 2004;23:932–46.
- Pauwels RA, Rabe KF. Burden and clinical features of chronic obstructive pulmonary disease (COPD). *Lancet* 2004;364:613–20.
- de Boer WI, Alagappan VK, Sharma HS. Molecular mechanisms in chronic obstructive pulmonary disease: potential targets for therapy. *Cell Biochem Biophys* 2007;47:131–48.
- Sadowska AM, Manuel YKB, De Backer WA. Antioxidant and anti-inflammatory efficacy of NAC in the treatment of COPD: discordant in vitro and in vivo dose-effects: a review. *Pulm Pharmacol Ther* 2007;20:9–22.
- Sadowska AM, Manuel-y-Keenoy B, De Backer WA. Inhibition of in vitro neutrophil migration through a bilayer of endothelial and epithelial cells using beta2-agonists: concomitant effects on IL-8 and elastase secretion and impact of glucocorticosteroids. *Pulm Pharmacol Ther* 2005;18:354–62.
- Han S, et al. Protection by antioxidants against toxicity and apoptosis induced by the sulphur mustard analog 2-chloroethylethyl sulphide (CEES) in Jurkat T cells and normal human lymphocytes. *Br J Pharmacol* 2004;141:795–802.
- Korkmaz A, et al. Molecular targets against mustard toxicity: implication of cell surface receptors, peroxynitrite production, and PARP activation. *Arch Toxicol* 2006;80:662–70.
- Naghii MR. Sulfur mustard intoxication, oxidative stress, and antioxidants. *Mil Med* 2002;167:573–5.
- Montuschi P, et al. Exhaled 8-isoprostane as an in vivo biomarker of lung oxidative stress in patients with COPD and healthy smokers. *Am J Respir Crit Care Med* 2000;162:1175–7.
- Golpon HA, et al. Emphysema lung tissue gene expression profiling. *Am J Respir Cell Mol Biol* 2004;31:595–600.
- Yoneda K, et al. Application of high-density DNA microarray to study smoke- and hydrogen peroxide-induced injury and repair in human bronchial epithelial cells. *J Am Soc Nephrol* 2003;14:S284–9.
- Cantin AM, et al. Normal alveolar epithelial lining fluid contains high levels of glutathione. *J Appl Physiol* 1987;63:152–7.
- Rahman I, MacNee W. Lung glutathione and oxidative stress: implications in cigarette smoke-induced airway disease. *Am J Physiol* 1999;277:L1067–88.
- Hayes JD, Pulford DJ. The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. *Crit Rev Biochem Mol Biol* 1995;30:445–600.
- Sharma A, et al. Glutathione S-transferases as antioxidant enzymes: small cell lung cancer (H69) cells transfected with hGSTA1 resist doxorubicin-induced apoptosis. *Arch Biochem Biophys* 2006;452:165–73.
- Astrup H. Genetic polymorphisms in human xenobiotic metabolizing enzymes as susceptibility factors in toxic response. *Mutat Res* 2000;464:65–76.
- Harrison DJ, et al. Frequency of glutathione S-transferase M1 deletion in smokers with emphysema and lung cancer. *Hum Exp Toxicol* 1997;16:356–60.

- 601 21. Ishii T, et al. Glutathione S-transferase P1 (GSTP1) polymorphism 661  
in patients with chronic obstructive pulmonary disease. *Thorax* 662  
1999;54:693–696.
- 603 22. Yim JJ, et al. Genetic susceptibility to chronic obstructive 663  
pulmonary disease in Koreans: combined analysis of polymorphic 664  
genotypes for microsomal epoxide hydrolase and glutathione 665  
S-transferase M1 and T1. *Thorax* 2000;55:121–5.
- 606 23. Yim JJ, et al. Lack of association between glutathione S-transferase 666  
P1 polymorphism and COPD in Koreans. *Lung* 2002;180:119–25. 667
- 608 24. He JQ, et al. Glutathione S-transferase variants and their interaction 668  
with smoking on lung function. *Am J Respir Crit Care Med* 2004; 669  
170:388–94.
- 610 25. Aynacioglu AS, et al. Protective role of glutathione S-transferase P1 670  
(GSTP1) Val105Val genotype in patients with bronchial asthma. 671  
*Br J Clin Pharmacol* 2004;57:213–17.
- 613 26. Beheshti J, et al. Mustard lung secrets: long term clinicopathological 672  
study following mustard gas exposure. *Pathol Res Pract* 2006; 673  
202:739–44.
- 615 27. Koyama H, Geddes DM. Genes, oxidative stress, and the risk of 674  
chronic obstructive pulmonary disease. *Thorax* 1998;53:S10–14.
- 616 28. MacNee W. Oxidants/antioxidants and COPD. *Chest* 2000;117: 675  
303S–17S.
- 618 29. Peterhans E. Oxidants and antioxidants in viral diseases: disease 676  
mechanisms and metabolic regulation. *J Nutr* 1997;127:962S–5S. 677
- 619 30. Schwarz KB. Oxidative stress during viral infection: a review. *Free 678  
Radic Biol Med* 1996;21:641–9.
- 620 31. Greene LS. Asthma, oxidant stress, and diet. *Nutrition* 1999;15: 679  
899–907.
- 622 32. Langen RC, Korn SH, Wouters EF. ROS in the local and systemic 680  
pathogenesis of COPD. *Free Radic Biol Med* 2003;35:226–35.
- 623 33. Husain K, et al. Effect of topically applied sulphur mustard on 681  
antioxidant enzymes in blood cells and body tissues of rats. *J Appl 682  
Toxicol* 1996;16:245–8.
- 625 34. Ebrahimi M, et al. Discrepancy between mRNA and protein 683  
expression of neutrophil gelatinase-associated lipocalin in bronchial 684  
epithelium induced by sulfur mustard. *J Biomed Biotechnol* 2010; 685  
2010:823131.
- 627 35. Baranova H, et al. Peculiarities of the GSTM1 0/0 genotype in 686  
French heavy smokers with various types of chronic bronchitis. 687  
*Hum Genet* 1997;99:822–6.
- 628 36. Sandford AJ, Pare PD. Genetic risk factors for chronic obstructive 688  
pulmonary disease. *Clin Chest Med* 2000;21:633–43.
- 629 37. Kushman ME, et al. Cytotoxicity and mutagenicity of 689  
dibenzo[a,l]pyrene and (+/-)-dibenzo[a,l]pyrene-11,12-dihydrodiol 690  
in V79MZ cells co-expressing either hCYP1A1 or hCYP1B1 691  
together with human glutathione-S-transferase A1. *Mutat Res* 2007; 692  
624:80–7.
- 630 38. Anttila S, et al. Immunohistochemical localization of glutathione 693  
S-transferases in human lung. *Cancer Res* 1993;53:5643–8. 694
- 631 39. Gilliland FD, et al. A theoretical basis for investigating ambient air 695  
pollution and children's respiratory health. *Environ Health Perspect* 696  
1999;107:403–7.
- 632 40. Hayes JD, Strange RC. Potential contribution of the glutathione 697  
S-transferase supergene family to resistance to oxidative stress. 698  
*Free Radic Res* 1995;22:193–207.
- 633 41. Strange RC, et al. Glutathione-S-transferase family of enzymes. 699  
*Mutat Res* 2001;482:21–6.
- 634 42. Hayes JD, Strange RC. Glutathione S-transferase polymorphisms 700  
and their biological consequences. *Pharmacology* 2000;61:154–66.
- 635 43. Khaheshi I, Keshavarz S, Imani Fooladi AA, et al. Loss of 701  
expression of TGF- $\beta$ s and their receptors in chronic skin lesions 702  
induced by sulfur mustard as compared with chronic contact 703  
dermatitis patients. *BMC Dermatol* 2011;11:2.
- 636 44. Nourani MR, Owada Y, Kitanaka N, et al. Localization of 704  
epidermal-type fatty acid binding protein in macrophages in 705  
advanced atretic follicles of adult mice. *J Mol Histol* 2005;36: 706  
391–400.
- 637 45. Nourani MR, Yazdani S, Habibi Roudkenar M, et al. HO1 mRNA 707  
and protein do not change in parallel in bronchial biopsies of 708  
patients after long term exposure to sulfur mustard. *Gene Regul 709  
Syst Biol* 2010;4:83–90.
- 638 46. Nourani MR, Ebrahimi M, Roudkenar MH, et al. Sulfur mustard 710  
induces expression of metallothionein-1A in human airway epithe- 711  
lial cells. 2011;4:413–19. 712  
713  
714  
715  
716  
717  
718  
719  
720